Triple-negative breast cancer

Hummingbird Bioscience and Dartmouth's Geisel School of Medicine to Co-Host 3rd Annual Virtual VISTA Symposium on March 27, 2024

Retrieved on: 
Mittwoch, März 13, 2024
DVM, Head, Q&A, Entrepreneurship, Immunotherapy, Patient, Triple-negative breast cancer, Immunology, Geisel School of Medicine, Columbia University, Cancer, Doctor of Philosophy, MD, Lung cancer, Yale School of Medicine, Neoplasm, Physician, VISTA, Management

SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience and Dartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET).

Key Points: 
  • SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience and Dartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET).
  • High VISTA expression in tumor correlates with poor survival in cancer patients and has been associated with a lack of response to other immune checkpoint inhibitors.
  • Pre-clinical data on VISTA biology and VISTA targeting have shown potent anti-tumor effects, and clinical readouts are expected this year.
  • The symposium will explore the important role of VISTA in cancer immunotherapy.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Mittwoch, Februar 28, 2024
NSCLC, Research, Gene, GSK, TIL, SITC, Growth, AP-1 transcription factor, Cell, International Society, NR4A3, Annual general meeting, Lung cancer, Society, Triple-negative breast cancer, GAAP, Biomarker, Phenotype, TNBC, Patient, Organization, Survival, TCR, Lyell, GSK plc, ISSCR, G&A, Literature, Workforce, IND, Corporation, Colorectal cancer, Vaccine

The study includes patients with relapsed or refractory triple-negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC).

Key Points: 
  • The study includes patients with relapsed or refractory triple-negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC).
  • The increase in fourth quarter 2023 non-GAAP R&D expenses was driven by an increase in research and laboratory costs primarily associated with clinical trials.
  • The decrease in both fourth quarter 2023 and annual 2023 G&A expenses were both primarily driven by decreases in non-cash stock-based compensation.
  • The decrease in 2023 non-GAAP G&A expenses was driven by a decrease in legal and corporate expenses.

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

Retrieved on: 
Dienstag, Februar 20, 2024
Senior, Docetaxel, TSX, Growth, Treatment, Frontiers, Triple-negative breast cancer, Immunity, TNBC, Volume, Patient, PDC, Survival, Syngenic, Research, Cancer, Vaccine

Sudocetaxel zendusortide is an investigational, first-in-class peptide-drug conjugate (PDC) that targets the sortilin receptor (SORT1) and expedites the internalization and delivery of the cytotoxic payload (docetaxel) directly into cancer cells.

Key Points: 
  • Sudocetaxel zendusortide is an investigational, first-in-class peptide-drug conjugate (PDC) that targets the sortilin receptor (SORT1) and expedites the internalization and delivery of the cytotoxic payload (docetaxel) directly into cancer cells.
  • The article, “Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing” appears in the “Cancer Immunity and Immunotherapy” section of the February (Volume 15) issue of the journal.
  • Additionally, combining sudocetaxel zendusortide with an anti-PD-L1 checkpoint inhibitor led to increases in tumor growth inhibition and median animal survival.
  • This realization supports the rationale for further exploration of the combination of sudocetaxel zendusortide with immunotherapy.”

Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens

Retrieved on: 
Freitag, März 8, 2024
Research, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Gene expression profiling, Breast cancer, Neoplasm, Taxane, Woman, Transcriptome, MD, MBCC, Cyclophosphamide, Anthracycline, PCR, MammaPrint, Risk, Conference, Symantec Endpoint Protection, AC-T, Patient, MP, Diagnosis, Triple-negative breast cancer, Blueprint, TC, Medical imaging

The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.

Key Points: 
  • The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.
  • ), investigates the associations between MammaPrint and BluePrint classifications, therapy regimen, and the likelihood of achieving a pathologic Complete Response (pCR).
  • The second poster, titled Prediction of chemotherapy benefit by MammaPrint® in patients with HR+HER2-early-stage breast cancer from real-world evidence studies (Audeh, W., et al.
  • Taken together, these findings indicate the utility of MammaPrint to predict neoadjuvant and adjuvant chemotherapy benefit in this patient population.

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer

Retrieved on: 
Montag, Februar 19, 2024
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Metabolism, Immunotherapy, AstraZeneca, News, Daiichi Sankyo, National Cancer Institute, Lung cancer, Triple-negative breast cancer, Immunology, Patient, Cleavage, Biopharmaceutical, Social media, Progression-free survival, Treatment, BLA, Docetaxel, IHC, DXD, Pharmacotherapy, NSCLC, Breast cancer, Gefitinib, PD-1, Safety, Lung, Pemetrexed, PFS, American Cancer Society, Pircher, Observational study, MD, Sapporo Medical University, Food, Cancer, ADC, OS, Immunoglobulin G, Death, Medicine, Pharmaceutical industry

AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy.

Key Points: 
  • AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy.
  • In patients with nonsquamous NSCLC, datopotamab deruxtecan showed a clinically meaningful PFS benefit and a numerically favorable OS trend.
  • Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Datopotamab deruxtecan has the potential to offer patients with previously treated advanced nonsquamous non-small cell lung cancer an effective and tolerable alternative to conventional chemotherapy.
  • Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.

Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024

Retrieved on: 
Dienstag, März 5, 2024
SAN, Neoplasm, VISTA, AACR, Lung cancer, Triple-negative breast cancer, HER3, Patient, Poster, Pharmaceutical industry

HMBD-001 is shown to potently block oncogenic signaling driven by HER3 mutations and could offer significant clinical benefit for patients with HER3 mutations across cancer types.

Key Points: 
  • HMBD-001 is shown to potently block oncogenic signaling driven by HER3 mutations and could offer significant clinical benefit for patients with HER3 mutations across cancer types.
  • The poster will highlight that more than 80% tumor growth inhibition is seen across multiple preclinical models with common HER3 mutations.
  • We look forward to discussing our recent advancements with the oncology research community at AACR," said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer, Hummingbird Bioscience.
  • Hummingbird Bioscience is recruiting patients with aberrant HER3 signaling, which includes selected HER3 mutations, in the company's ongoing Phase Ib trial (NCT05919537).

Michele Young named one of USA TODAY's Women of the Year along with other heroines who have made a significant impact in their communities and across the country

Retrieved on: 
Donnerstag, Februar 29, 2024
Breast cancer, Michele, Woman, Survivor, Violence, The Cincinnati Enquirer, Radiology, USA Today, Suicide, Nature, Government, Supreme Court of Ohio, Cincinnati Public Schools, Life, Vaccine, Risk, Crime, Marie Curie, Character, Ohio Department of Health, History, Cancer, NBC, Triple-negative breast cancer, School, AJC, Editing, Family, Bullying, Disease, HB, Diagnosis, Science, Movement, Child, Supreme court, Research, Social justice, Birth control

CINCINNATI, Feb. 29, 2024 /PRNewswire/ -- Today Michele Young, an acclaimed Cincinnati lawyer, mother of five, advanced-stage breast cancer survivor and tireless advocate for social justice was named one of USA Today's Women of the Year.

Key Points: 
  • "Imagine the extraordinary potential that will be unleashed when an epidemic that strikes one in seven women is erased from this earth," said Young.
  • Michele witnessed changes in breast cancer science first-hand as a stage 4 patient in the cancer wards of our nation.
  • She learned of Cleveland Clinic's Dr. Thomas Budd who is studying a vaccine in those with triple-negative breast cancer.
  • Or those women who are killed by the disease – one woman every 14 seconds – taking her from her world," said Young.

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Retrieved on: 
Donnerstag, Februar 15, 2024
Closing, Neoplasm, Algorithm, Recurrence, Epigenomics, Oxford Nanopore Technologies, Doctor of Philosophy, LOS, LON, AI, MD, Blood, LOI, Partnership, Cancer, Lung cancer, Liquid biopsy, TP53, Cell, Metabolomics, Diagnosis, Triple-negative breast cancer, Physical examination, Carcinoma, Patient, Proteomics, Genomics, Deep learning, HNC, Nvidia, DNA, IVD, NVIDIA, Medical imaging

LOS ANGELES and AMSTERDAM, Feb. 15, 2024 (GLOBE NEWSWIRE) -- GEDiCube (moving forward RenovaroCube), a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.

Key Points: 
  • Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
  • Cyclomics’ 4th generation liquid biopsy genomics platform is the first truly “Omni-Omic” blood test ready for AI application.
  • Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
  • The focus is on early cancer- and early recurrence detection, prediction of response to therapy, and personalized treatment, all via liquid biopsy tests.

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Retrieved on: 
Dienstag, Februar 13, 2024
Closing, Neoplasm, Algorithm, Recurrence, Epigenomics, Oxford Nanopore Technologies, Doctor of Philosophy, LOS, LON, MD, Blood, LOI, Partnership, Cancer, Lung cancer, Liquid biopsy, TP53, Cell, Metabolomics, Diagnosis, Triple-negative breast cancer, Physical examination, Carcinoma, Patient, Proteomics, Genomics, Deep learning, HNC, Nvidia, DNA, IVD, NVIDIA, Medical imaging

LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) -- GEDi Cube Intl Ltd., a London and Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.

Key Points: 
  • Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
  • The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
  • Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement.
  • I consider that to be a significant step towards bringing early detection of cancer to its inflection point.”

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Retrieved on: 
Dienstag, Januar 30, 2024
SAN, Breast, University, International, MD Anderson Cancer Center, FACMG, FDA, VAF, Bone marrow, SVS, Cytogenetics, Genome, LRS, OGM, University of Toronto, TNBC, Pressure, Biomarker, PARP, Quality control, Karyotype, HRD, Saint John Regional Hospital, T-ALL, CRISPR, Curie Institute, Triple-negative breast cancer, In situ hybridization, FISH, Frog, Genomics, Hospital, HRP, Patient, Marfan syndrome, Fluorescence, NIST, DSM-IV codes, Doctor of Philosophy, Cancer, Multiple myeloma, Workflow, Gene editing, Research, KT, Cell, Down syndrome, NGS, Vaccine

During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.
  • OGM is helping to unravel persistent, complex mysteries in genetic disease that impact people, even in more common disorders like Down syndrome and Marfan syndrome.
  • OGM has the potential to meet the key requirements of the cell and gene therapy community.
  • “I would encourage anyone who was unable to attend live to login, view these presentations and see how bright the future of cytogenetics is with OGM.”